Donepezil and memantine for moderate-to-severe Alzheimer's disease.

By R. Howard, R. McShane, J. Lindesay, C. Ritchie, A. Baldwin, R. Barber, A. Burns, T. Dening, D. Findlay, C. Holmes and 23 more. New England Journal of Medicine, 2012

671 citations recorded by the source corpus.

Subfields: Pharmacology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/59be90c59732ace9d10ad1f2add2d3da9438b4e0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pharmacology

1. Michael D. Geschwind
2. Michael G. Erkkinen
3. Mee‐Ohk Kim

In Physiology

1. Michael D. Geschwind
2. Michael G. Erkkinen
3. Mee‐Ohk Kim

In Psychiatry and Mental health

1. Michael D. Geschwind
2. Michael G. Erkkinen
3. Mee‐Ohk Kim

Citations in the corpus

• Therapeutics of Alzheimer's disease: Past, present and future. (2014, background): “A number of investigators have looked at the possible advantage of its combining memantine with AChEI in AD (Atri et al., 2013; Dantoine et al., 2006; Howard et al., 2012; Lopez et al., 2009; Porsteinsson et al., 2008; Riepe et al., 2007; Tariot et al., 2004).”
• Alzheimer’s disease drug-development pipeline: few candidates, frequent failures (2014, neutral): “2014 receptor AD antagonist (memantine) [3,4].”
• Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “…believed to work by suppressing glutamatemediated excitotoxicity, has been shown to reduce clinical deterioration on several scales in patients with moderate-to-severe AD compared with controls (Howard et al. 2012; Reisberg et al. 2003), but not in patients with mild disease (McShane et al. 2006).”